Savvy Trades and Investments

[steeledge]

db7, re: DMTK/W you're welcome! looks like things are starting to come together, and the stock is starting to get noticed. Tuesday's news, while having a delayed reaction in the stock price, was quite good i think. The warrants have more than doubled with good volume.


https://finance.yahoo.com/news/dermtech-test-included-expert-panel-120000779.html

DermTech’s Test Included in Expert Panel’s Clinical Management Recommendations for Cutaneous Melanoma

Business Wire•October 15, 2019

LA JOLLA, Calif.--(BUSINESS WIRE)--

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a global leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion in Clinical Management Recommendations, “Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Process Assessment” published in the September issue of SKIN. The publication can be accessed at http://jofskin.org/index.php/skin/article/view/663.

A panel of dermatologists and dermatopathologists with expertise in pigmented lesions, melanoma, and gene expression technology evaluated commercially available gene expression tests to provide recommendations for use in specific clinical situations. The expert panel recommended use of the non-invasive PLA (Pigmented Lesion Assay), or 2-Gene Expression Profile test, in cases in which patients present with atypical lesions requiring additional assessment beyond visual inspection in order to inform the decision to surgically biopsy. This recommendation closely aligns with the previously published utility data on the PLA (Ferris et al., Melanoma Research, 2018), which found that clinicians appropriately biopsied all PLA positive lesions while managing 99% of PLA negative lesions with surveillance and without surgical biopsies.

Senior author Dr. Darrell Rigel, Department of Dermatology, New York University Medical Center, commented, “Developments in genomics are expanding the diagnostic tools available to melanoma patients. The PLA specifically can aid clinicians in the biopsy decision of suspicious lesions and its 99% negative predictive value can help to rule-out melanoma with a high degree of certainty.”

“We are proud to be included in the panel’s clinical management recommendations,” said Todd Wood, Chief Commercial Officer for DermTech. “We are glad that experts are recognizing the clinical value of our non-invasive genomic test for melanoma, which enhances early detection while reducing unnecessary biopsies and scarring of non-cancerous lesions. We are excited to bring the technology to patients.”